Table 2. Clinical characteristics of NSCLC patients with EGFR-TKI sensitizing mutation.

Variable	EGFR wild type (n=164)	EGFR mutant type (n=66)	p-value
Age (yr)	66.1±0.78	62.4±1.16	0.012
Sex			<0.001
Male	116 (70.7)	22 (33.3)
Female	48 (29.3)	44 (66.7)
Smoking history			<0.001
Never smoker	59 (36.0)	47 (71.2)
Ex-smoker	46 (28.0)	7 (10.6)
Current smoker	59 (36.0)	12 (18.2)
Histologic type			0.002*
Adenocarcinoma	130 (80.2)	64 (97.0)
Squamous cell carcinoma	30 (18.5)	2 (3.0)
Others	2 (1.2)	0 (0)
Stage			0.133
I	13 (7.9)	10 (15.2)
II	7 (4.3)	2 (3.0)
III	31 (18.9)	6 (9.1)
IV	113 (68.9)	48 (72.7)
PD-L1 expression (22C3)			0.156
<1%	61 (37.2)	30 (45.5)
≥1%	103 (62.8)	36 (54.5)

Values are presented as mean±SD or number (%).

^*Fisher's exact test.

NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; PD-L1: programmed death-ligand 1.